| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Transcarent | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.13B | Series D-1 | 4/7/2025 | $700M | $3.16B | $20.48 | Undisclosed Investors | ||||
 | Medline Industries | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Papa | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $241.79M | Series D | 11/4/2021 | $150M | $1.39B | $50.35 | SoftBank, TCG, Tiger Global Management, Canaan, Initialized Capital, Seven Seven Six | ||||
 | PathAI | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.49M | Series C | 5/19/2021 | $165M | $1.11B | $29.50 | D1 Capital Partners, Kaiser Permanente, General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, Bristol-Myers Squibb Company, Labcorp, Merck Global Health Innovation Fund | ||||
 | Virta Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $395.18M | Series F | 12/29/2025 | $30.15M | $1.2B | $1.46 | Undisclosed Investors | ||||
 | Xaira Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1B | Series A | 4/23/2024 | $500M | $2.65B | $2.50 | ARCH Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared, SV Angel, AIM13, Breyer Capital, Deviation Capital, Foresite Labs, JSL Health Capital, Longwood Fund, Sahsen Ventures, WRF Capital | ||||
 | Eko Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $327.66M | Series D | 6/5/2024 | $41M | $271.32M | $1.72 | ARTIS Ventures, Highland Capital Partners, NTTVC, Questa Capital | ||||
 | Insitro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.26B | Series C | 3/15/2021 | $400M | $2.57B | $18.29 | CPP Investments, Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, Softbank | ||||
 | K Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $475M | Series G-1 | 6/4/2026 | $20M | $816.97M | $9.82 | Undisclosed Investors | ||||
 | Ambience Healthcare | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.59M | Series C | 7/29/2025 | $210M | $1.24B | $37.98 | Oak HC/FT, Andreessen Horowitz, OpenAI, Kleiner Perkins, Optum Ventures, Frist Cressey Ventures, Town Hall Ventures, Smash Capital, Georgian, Founders Circle Capital | ||||
 | Axtria | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.97M | Series E | 5/13/2021 | $100.1M | $920.88M | $9.53 | Bain Capital Tech Opportunities | ||||
 | BillionToOne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $396.39M | Series D | 6/21/2024 | $130.47M | $1.25B | $28.02 | Premji Invest, Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years | ||||
 | Cambrian | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $640.00K | -- | 1 | Not available | -- | -- | $351.19M | Series D | 6/29/2026 | $100M | $386.97M | $2.00 | Undisclosed Investors | ||||
 | Capsule | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180.56M | Series E | 2/13/2023 | $100M | $458.12M | $2.93 | Cox Enterprises, SeedFord Partners | ||||
 | Carbon Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $688.42M | Super Series Senior-2 | 6/4/2025 | $20.2M | $485.04M | $1.71 | Undisclosed Investors | ||||
 | Cognito Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Pelage | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $150.75M | Series B | 10/15/2025 | $120M | $314.7M | $7.23 | ARCH Venture Partners, GV, Main Street Advisors, Visionary Ventures, YK Bioventures | ||||
 | Rula | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.55M | Series C-1 | 2/17/2026 | $6.24M | $2.4B | $11.32 | Undisclosed Investors | ||||
 | Science Corporation | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $494.02M | Series C | 3/5/2026 | $230.05M | $1.5B | $8.36 | Khosla Ventures, Lightspeed Venture Partners, Y Combinator, In-Q-Tel, Quiet Capital, Mangusta Capital, Octant Ventures, RRE Ventures | ||||
 | Cytonics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Emulate | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $205.31M | Series F-1 | 3/8/2024 | $54.02M | $132.81M | $1.17 | Undisclosed Investors | ||||
 | Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | ||||
 | Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.5M | Series C | 6/25/2024 | $100M | $438.18M | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | ||||
 | HeartFlow | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $755.52M | Series F | 4/6/2023 | $174.86M | $546.5M | $2.85 | Bain Capital, Janus Henderson Investors, Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, Wellington Management | ||||